Literature DB >> 28508981

Partial remission by cyclosporine monotherapy in a patient with membranous nephropathy superimposed diabetic nephropathy.

Yoshiyuki Oshiro1, Hisataka Tanaka2, Fumiko Kawasaki2, Niro Okimoto2.   

Abstract

It has been noted that cyclosporine A (CsA) is an effective drug for membranous nephropathy (MN). Diabetes is a common disease that sometimes causes nephrotic syndrome. We report the case of an 89-year-old woman with type 2 diabetes mellitus who exhibited nephrotic syndrome. Examination of a renal biopsy indicated MN and she was prescribed CsA as monotherapy. Her edema subsided and she achieved partial remission. This is the first report of a patient in diabetic condition with MN having achieved partial remission after CsA monotherapy without steroid therapy. The use of steroid in patients with diabetes may worsen their diabetic condition, especially if they are of very advanced age. CsA monotherapy may be useful for diabetic patients with MN.

Entities:  

Keywords:  Cyclosporine; Diabetes; Membranous nephropathy

Year:  2016        PMID: 28508981      PMCID: PMC5411648          DOI: 10.1007/s13730-016-0228-z

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  8 in total

1.  Non-diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome.

Authors:  Tayebeh Soleymanian; Gholamreza Hamid; Mohammad Arefi; Iraj Najafi; Mohammad Reza Ganji; Manuchehr Amini; Monirosadat Hakemi; Mohammad Reza Mohajeri Tehrani; Bagher Larijani
Journal:  Ren Fail       Date:  2015-02-16       Impact factor: 2.606

2.  Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.

Authors:  Natalia Polanco; Elena Gutiérrez; Adelardo Covarsí; Francisco Ariza; Agustín Carreño; Ana Vigil; José Baltar; Gema Fernández-Fresnedo; Carmen Martín; Salvador Pons; Dolores Lorenzo; Carmen Bernis; Pilar Arrizabalaga; Gema Fernández-Juárez; Vicente Barrio; Milagros Sierra; Ines Castellanos; Mario Espinosa; Francisco Rivera; Aniana Oliet; Francisco Fernández-Vega; Manuel Praga
Journal:  J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 10.121

3.  Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.

Authors:  Efstathios Alexopoulos; Aikaterini Papagianni; Mzia Tsamelashvili; Maria Leontsini; Dimitrios Memmos
Journal:  Nephrol Dial Transplant       Date:  2006-09-12       Impact factor: 5.992

4.  Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan.

Authors:  Hideo Shiiki; Takao Saito; Yoshiharu Nishitani; Tetsuya Mitarai; Noriaki Yorioka; Ashio Yoshimura; Hitoshi Yokoyama; Shinichi Nishi; Yasuhiko Tomino; Kiyoshi Kurokawa; Hideto Sakai
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

5.  Prevalence of nondiabetic renal disease in diabetic patients.

Authors:  Tam T Pham; John J Sim; Dean A Kujubu; In-Lu Amy Liu; Victoria A Kumar
Journal:  Am J Nephrol       Date:  2007-05-09       Impact factor: 3.754

Review 6.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis.

Authors:  Laurence Beck; Andrew S Bomback; Michael J Choi; Larry B Holzman; Carol Langford; Laura H Mariani; Michael J Somers; Howard Trachtman; Meryl Waldman
Journal:  Am J Kidney Dis       Date:  2013-07-18       Impact factor: 8.860

7.  A review of therapeutic studies of idiopathic membranous glomerulopathy.

Authors:  S L Hogan; K E Muller; J C Jennette; R J Falk
Journal:  Am J Kidney Dis       Date:  1995-06       Impact factor: 8.860

8.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.

Authors:  Andrew Howman; Tracey L Chapman; Maria M Langdon; Caroline Ferguson; Dwomoa Adu; John Feehally; Gillian J Gaskin; David R W Jayne; Donal O'Donoghue; Michael Boulton-Jones; Peter W Mathieson
Journal:  Lancet       Date:  2013-01-09       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.